Recent progress in polymer therapeutics as nanomedicines

Handbook of Harnessing Biomaterials in Nanomedicine

Volumn , Issue , 2012, Pages 77-122

  Baabur Cohen, Hemda ^a   Omer, Liora ^a   Satchi Fainaro, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84881745186     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4032/9789814364270     Document Type: Chapter

References (166)

1. Ringsdorf, H., Structure and properties of pharmacologically active polymers. J. Polym. Sci. Symp., 1975. 51: p. 135-153.
2. Matsumura, Y. and H. Maeda, A New Concept for Macromolecular Therapeutics in Cancer-Chemotherapy - Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs. Cancer Research, 1986. 46(12): p. 6387-6392.
3. Maeda, H., et al., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release, 2000. 65(1-2): p. 271-284.
4. Sanchis, J., et al., Polymer-drug conjugates for novel molecular targets. Nanomedicine (London). 5(6): p. 915-935.
5. Alexis, F., et al., Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm, 2008. 5(4): p. 505-515.
6. Davis, M.E., The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm, 2009. 6(3): p. 659-668.
7. Perrault, S.D., et al., Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett, 2009. 9(5): p. 1909-1915.
8. Alberts B., B.D., Johnson A., Lewis J., Raf M., Roberts K., Walter P., Essential Cell Biology. 1998, New York: Garland Publishing. 472-477.
9. Pan H. and K. J., Multifunctional Water-Soluble Polymers for Drug Delivery, in Multifunctional Pharmaceutical Nanocarriers, M. Ferrari, Editor. 2008, Springer. p. 81-142.
10. Satchi-Fainaro, R., R. Duncan, and C.M. Barnes, Polymer therapeutics for cancer: Current status and future challenges, in Polymer Therapeutics II: Polymers as Drugs, Conjugates and Gene Delivery Systems. 2006, Springer-Verlag Berlin: Berlin. p. 1-65.
11. Markman, M., Improving the toxicity profile of chemotherapy for advanced ovarian cancer: a potential role for CT-2103. J Exp Ther Oncol, 2004. 4(2): p. 131-136.
12. Langer, C.J., CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clin Lung Cancer, 2004. 6 Suppl 2: p. S85-S88.
13. Pawar, R., et al., A. Polysaccharides as carriers of bioactive agents for medical application. Natural-Based Polymers for Biomedical Applications, ed. R.L.E. Reis. 2008, New York: Woodhead Pub. 50.
14. Caliceti, P., S. Salmaso, and S. Bersani, Polysaccharide-base anticancer prodrugs. Macromolecular Anticancer Therapeutics, ed. P.E. Harivardhan R.L.; Couvreur. 2010, New York: Humana Press. 163- 220.
15. Pasut, G. and F.M. Veronese, PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev, 2009. 61(13): p. 1177-1188.
16. Duncan, R., Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. Adv Drug Deliv Rev, 2009. 61(13): p. 1131-1148.
17. Kopecek, J. and P. Kopeckova, HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev, 2010. 62(2): p. 122-149.
18. Chun, L., Poly(L-glutamic acid)-anticancer drug conjugates. Adv Drug Deliv Rev, 2002. 54: p. 695-713.
19. Bisht, S. and A. Maitra, Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2009. 1(4): p. 415-425.
20. Baldwin, A.D. and K.L. Kiick, Polysaccharide-modified synthetic polymeric biomaterials. Biopolymers, 2010. 94(1): p. 128-140.
21. Grzelinski, M., et al., RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Human Gene Ther, 2006. 17(7): p. 751-766.
22. Schafert, D. and E. Wagner, Gene therapy progress and prospects: synthetic polymer-based systems. Gene Ther, 2008. 15(16): p. 1131- 1138.
23. Danhauser-Riedl, S., et al., Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New Drugs, 1993. 11(2-3): p. 187-195.
24. Singh, R.S., G.K. Saini, and J.F. Kennedy, Pullulan: microbial sources, production and applications. Carbohyr Polym, 2008. 73: p. 515-531.
25. Leather, T.D., Production and applications of pullulan. Appl. Microbiol Biotechnol, 2003. 62: p. 468-473.
26. Kim, S., et al., Insulinotropic activity of sulfonylurea/pullulan conjugate in rat islet microcapsule. Biomaterials, 2003. 24(26): p. 4843-4851.
27. Clementi, C., et al., Dendritic Poly(ethylene glycol) bearing Paclitaxel and Alendronate for targeting bone neoplasms. Mol Pharm, 2011. 8(4): p. 1063-1072.
28. Vasey, P.A., et al., Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res, 1999. 5(1): p. 83-94.
29. Teodorescu, M. and K. Matyjaszewski, Atom transfer radical polymerization of (meth)acrylamides. Macromolecules, 1999. 32: p. 4826-4831.
30. Teodorescu, M. and K. Matyjaszewski, Controlled polymerization of (meth)acrylamides by atom transfer radical polymerization. Macrol. Rapid Commun., 2000. 21: p. 190-194.
31. Scales, C.W., et al., Direct, controlled synthesis of the nonimmunogenic, hydrophilic polymer, poly(N-(2-hydroxypropyl)methacrylamide) via RAFT in aqueous media. Biomacromolecules, 2005. 6(4): p. 1846- 1850.
32. Segal, E., et al., Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One, 2009. 4(4): p. e5233.
33. Chytil, P., et al., N-(2-Hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin for cell-specific or passive tumour targeting. Synthesis by RAFT polymerisation and physicochemical characterisation. Eur J Pharm Sci, 2010. 41(3-4): p. 473-482.
34. Ulbrich, K., et al., Polymeric conjugates of drugs and antibodies for site-specific drug delivery. Macromol Symp, 1996. 103: p. 177-192.
35. Putnam, D. and J. Kopecek, Polymer conjugates with anticancer activity. Biopolymers II, 1995. 122: p. 55-123.
36. Ulbrich, K. and V. Subr, Polymeric anticancer drugs with pH-controlled activation. Adv Drug Deliv Rev, 2004. 56(7): p. 1023-1050.
37. Kratz, F., U. Beyer, and M.T. Schutte, Drug-polymer conjugates containing acid-cleavable bonds. Crit Rev Ther Drug Carrier Syst, 1999. 16(3): p. 245-288.
38. Rodrigues, P.C.A., et al., Correlation of the acid-sensitivity of polyethylene glycol daunorubicin conjugates with their in vitro antiproliferative activity. Bioorg Med Chem, 2006. 14(12): p. 4110-4117.
39. Meng, F.H., W.E. Hennink, and Z. Zhong, Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials, 2009. 30(12): p. 2180-2198.
40. Kopeček, J., et al., Synthetic polymeric drugs, U.S. Patent, Editor. 1991.
41. Miller, K., et al., Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem Int Ed Engl, 2009. 48(16): p. 2949-2954.
42. Dubowchik, G.M., et al., Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem, 2002. 13(4): p. 855-869.
43. Liu, C., et al., Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res, 2003. 63(11): p. 2957-2964.
44. Stern, L., et al., A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain. Bioconjug Chem, 2009. 20(3): p. 500-510.
45. Kratz, F., et al., Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates. Bioorg Med Chem Lett, 2001. 11(15): p. 2001-2006.
46. Kratz, F., et al., Prodrug strategies in anticancer chemotherapy. ChemMedChem, 2008. 3(1): p. 20-53.
47. Apostolovic, B., et al., Hybrid polymer therapeutics incorporating bioresponsive, coiled coil peptide linkers. Biomacromolecules, 2010. 11(5): p. 1187-1195.
48. Strebhardt, K. and A. Ullrich, Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer, 2008. 8(6): p. 473-480.
49. Parveen, S. and S.K. Sahoo, Polymeric nanoparticles for cancer therapy. J Drug Target, 2008. 16(2): p. 108-123.
50. Ishida, T. , et al., Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim Biophys Acta, 2001. 1515(2): p. 144-158.
51. Ryppa, C., et al., In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3. Int J Pharm, 2009. 368(1-2): p. 89-97.
52. Polyak, D., et al., Development of PEGylated doxorubicin-E-[c(RGDfK)2] conjugate for integrin-targeted cancer therapy. Polym. Adv. Technol., 2011. 22: p. 103-113.
53. Kaneshiro, T.L. and Z.R. Lu, Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials, 2009. 30(29): p. 5660-5666.
54. Oba, M., et al., Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing alphavbeta3 and alphavbeta5 integrins. Bioconjug Chem, 2007. 18(5): p. 1415- 1423.
55. Arnaout, M.A., S.L. Goodman, and J.P. Xiong, Coming to grips with integrin binding to ligands. Curr Opin Cell Biol, 2002. 14(5): p. 641- 651.
56. Adar, L., et al., Pro-apoptotic peptide-polymer conjugates to induce mitochondrial-dependent cell death. Polym Adv Technol, in press, 2010.
57. Gragoudas, E.S., et al., Pegaptanib for neovascular age-related macular degeneration. N Engl J Med, 2004. 351(27): p. 2805-2816.
58. Milane, L.J., Z. Duan, and M.M. Amiji, Development of EGFR-targeted polymer blend nanocarriers for Paclitaxel/Lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol Pharm, 2010. 8(1): p. 185-203.
59. Shamay, Y., et al., E-selectin binding peptide-polymer-drug conjugates and their selective cytotoxicity against vascular endothelial cells. Biomaterials, 2009. 30(32): p. 6460-6468.
60. Kneuer, C., et al., Selectins - potential pharmacological targets? Drug Discov Today, 2006. 11(21-22): p. 1034-1040.
61. Park, K., et al., Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate. Biomaterials, 2010. 31(19): p. 5258-5265.
62. Canal, F., et al., Relevance of folic acid/polymer ratio in targeted PEG-epirubicin conjugates. J Control Release, 2010. 146(3): p. 388-399.
63. Pinhassi, R.I., et al., Arabinogalactan-folic acid-drug conjugate for targeted delivery and target-activated release of anticancer drugs to folate receptor-overexpressing cells. Biomacromolecules. 11(1): p. 294-303.
64. Pasut, G., et al., Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid. J Control Release, 2008. 127(3): p. 239-248.
65. Yang, X., et al., Tumor-targeting, pH-responsive, and stable unimolecular micelles as drug nanocarriers for targeted cancer therapy. Bioconjug Chem.
66. Bae, Y., N. Nishiyama, and K. Kataoka, In vivo antitumor activity of the folate-conjugated pH-sensitive polymeric micelle selectively releasing adriamycin in the intracellular acidic compartments. Bioconjug Chem, 2007. 18(4): p. 1131-1139.
67. Thomas, T.P., et al., Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem, 2005. 48(11): p. 3729- 3735.
68. Daniels, T.R., et al., The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol, 2006. 121(2): p. 159-176.
69. Gomme, P.T., K.B. McCann, and J. Bertolini, Transferrin: structure, function and potential therapeutic actions. Drug Discov Today, 2005. 10(4): p. 267-273.
70. Tsukagoshi, S., A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot) - outline of pre-clinical and clinical studies. Gan To Kagaku Ryoho, 2002. 29(9): p. 1675-1687.
71. Dharap, S.S., et al., Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J Control Release, 2003. 91(1-2): p. 61-73.
72. Khandare, J.J., et al., Novel polymeric prodrug with multivalent components for cancer therapy. J Pharmacol Exp Ther, 2006. 317(3): p. 929-937.
73. Heyns, C.F., et al., Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int, 2003. 92(3): p. 226-231.
74. O'Hare, K.B., et al., Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone: in vitro and in vivo evaluation against murine melanoma. J Drug Target, 1993. 1(3): p. 217-229.
75. Hopewel, J.W., et al., Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent. Hum Exp Toxicol, 2001. 20(9): p. 461-470.
76. Seymour, L.W., et al., N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice. Br J Cancer, 1991. 63(6): p. 859-866.
77. Hu, C.-M.J., et al., Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol Pharm, 2010. 7(3): p. 914-920.
78. Dhal, P.K., et al., Functional polymers as therapeutic agents: concept to market place. Adv Drug Deliv Rev, 2009. 61(13): p. 1121-1130.
79. Vicent, M.J., H. Ringsdorf, and R. Duncan, Polymer therapeutics: clinical applications and challenges for development. Adv Drug Deliv Rev, 2009. 61(13): p. 1117-1120.
80. Stedronsky, E.R., Interaction of bile-acids and cholesterol with nonsystemic agents having hypocholesterolemic properties. Biochim Biophys Acta Lipids Lipid Metab, 1994. 1210(3): p. 255-287.
81. Mandeville, W.H. and D.I. Goldberg, The sequestration of bile acids, a non-absorbed method for cholesterol reduction. A review. Curr Pharm Des, 1997. 3(1): p. 15-28.
82. Cameron, N.S., A. Eisenberg, and G.R. Brown, Amphiphilic block copolymers as bile acid sorbents: 1. Synthesis of polystyrene-b-poly(N,N,N-trimethylammoniumethylene acrylamide chloride). Biomacromolecules, 2002. 3(1): p. 116-123.
83. Zhang, L., et al., Enhancing the "stickiness" of bile acids to cross-linked polymers: a bioconjugate approach to the design of bile acid sequestrants. Bioconjug Chem, 2000. 11(3): p. 397-400.
84. Huval, C.C., et al., Ammonium and guanidinium functionalized hydrogels-as bile acid sequestrants: Synthesis, characterization, and biological properties. J Macromol Sci Pure Appl Chem, 2004. A41(3): p. 231- 244.
85. Huval, C.C., et al., Syntheses of hydrophobically modified cationic hydrogels by copolymerization of alkyl substituted diallylamine monomers and their use as bile acid sequestrants. Eur Polym J, 2004. 40(4): p. 693-701.
86. Florentin, M., et al., Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Curr Med Res Op, 2008. 24(4): p. 995-1009.
87. Staels, B. and F. Kuipers, Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs, 2007. 67(10): p. 1383-1392.
88. Huval, C.C., et al., Novel cholesterol lowering polymeric drugs obtained by molecular imprinting. Macromolecules, 2001. 34(6): p. 1548-1550.
89. Wang, Y.J., et al., Specific binding of cholic acid by cross-linked polymers prepared by the hybrid imprinting method. Polymer, 2007. 48(19): p. 5565-5571.
90. Tamaru, S. and I. Hamachi, Recent progress of phosphate derivatives recognition utilizing artificial small molecular receptors in aqueous media. Recognit Anions, 2008. 129: p. 95-125.
91. Gale, P.A., S.E. Garcia-Garrido, and J. Garric, Anion receptors based on organic frameworks: highlights from 2005 and 2006. Chem Soc Rev, 2008. 37(1): p. 151-190.
92. Holmes-Farley, S.R., et al., Design and characterization of sevelamer hydrochloride: A novel phosphate-binding pharmaceutical. J Macromol Sci Pure Appl Chem, 1999. A36(7-8): p. 1085-1091.
93. Amin, N., The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol Dial Transplant, 2002. 17(2): p. 340-345.
94. Goldsmith, D.R., et al., Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Drugs, 2008. 68(1): p. 85-104.
95. Liu, Z.D. and R.C. Hider, Design of clinically useful iron(III)-selective chelators. Med Res Rev, 2002. 22(1): p. 26-64.
96. Raymond, K.N., Biomimetic metal encapsulation. Coordination Chem Rev, 1990. 105: p. 135-153.
97. Polomoscanik, S.C., et al., Hydroxamic acid-containing hydrogels for nonabsorbed iron chelation therapy: Synthesis, characterization, and biological evaluation. Biomacromolecules, 2005. 6(6): p. 2946-2953.
98. Zhou, T., et al., Iron binding dendrimers: A novel approach for the treatment of haemochromatosis. J Med Chem, 2006. 49(14): p. 4171- 4182.
99. Zhou, T., et al., Synthesis and iron(III)-chelating properties of novel 3-hydroxypyridin-4-one hexadentate ligand-containing copolymers. Biomacromolecules, 2008. 9(5): p. 1372-1380.
100. Louie, T.J., et al., Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis, 2006. 43(4): p. 411-420.
101. Vercruysse, K.P. and G.D. Prestwich, Hyaluronate derivatives in drug delivery. Crit Rev Ther Drug Carrier Syst, 1998. 15(5): p. 513-555.
102. Waddell, D.D., The tolerability of viscosupplementation: low incidence and clinical management of local adverse events. Curr Med Res Opin, 2003. 19(7): p. 575-580.
103. Bellamy, N., et al., Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev, 2006(2): p. CD005321.
104. Bhardwaj, R. and M.C. Parker, Impact of adhesions in colorectal surgery. Colorectal Dis, 2007. 9 Suppl 2: p. 45-53.
105. Boland, G.M. and R.J. Weigel, Formation and prevention of postoperative abdominal adhesions. J Surg Res, 2006. 132(1): p. 3-12.
106. Zeng, Q., et al., Efficacy and safety of Seprafilm for preventing postoperative abdominal adhesion: systematic review and meta-analysis. World J Surg, 2007. 31(11): p. 2125-2131; discussion 2132.
107. Vasey, P.A., et al., Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents - Drug-polymer conjugates. Clin Cancer Res, 1999. 5(1): p. 83-94.
108. Seymour, L.W., et al., Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol, 2002. 20(6): p. 1668-1676.
109. Seymour, L.W., et al., Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol, 2009. 34(6): p. 1629-1636.
110. Vercauteren, R., E. Schacht, and R. Duncan, Effect of the Chemical Modification of Dextran on the Degradation by Rat Liver Lysosomal Enzymes. J Bioactive Compatible Polym, 1992. 7(4): p. 346-357.
111. Auzenne, E., et al., Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma. Clin Cancer Res, 2002. 8(2): p. 573-581.
112. http://www.celltherapeutics.com/pdf/OPAXIO_facts-4pg.pdf
113. Paz-Ares, L., et al., Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer, 2008. 98(10): p. 1608-1613.
114. O'Brien, M.E., et al., Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol, 2008. 3(7): p. 728-734.
115. Langer, C.J., et al., Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol, 2008. 3(6): p. 623-630.
116. Wheate, N.J., et al., The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans, 2010. 39(35): p. 8113-8127.
117. Rademaker-Lakhai, J.M., et al., A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res, 2004. 10(10): p. 3386-3395.
118. Nowotnik, D.P. and E. Cvitkovic, ProLindac (TM) (AP5346): A review of the development of an HPMA DACH platinum polymer therapeutic. Adv Drug Deliv Rev, 2009. 61(13): p. 1214-1219.
119. Yurkovetskiy, A.V. and R.J. Fram, XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer. Adv Drug Deliv Rev, 2009. 61(13): p. 1193-1202.
120. Cheng, J.J., et al., Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug Chem, 2003. 14(5): p. 1007-1017.
121. Davis, M.E., Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv Drug Deliv Rev, 2009. 61(13): p. 1189-1192.
122. Folkman, J., Tumor angiogenesis: therapeutic implications. N Engl J Med, 1971. 285(21): p. 1182-1186.
123. Satchi-Fainaro, R., Targeting tumor vasculature: reality or a dream? J Drug Target, 2002. 10(7): p. 529-533.
124. Matsumura, Y. and H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res, 1986. 46(12 Pt 1): p. 6387-6392.
125. Joralemon, M.J., S. McRae, and T. Emrick, PEGylated polymers for medicine: from conjugation to self-assembled systems. Chem Commun (Camb), 2010. 46(9): p. 1377-1393.
126. Winter, T.A., et al., Treatment of Crohn's disease with certolizumab pegol. Expert Rev Clin Immunol, 2007. 3(5): p. 683-694.
127. Ton, N.C., et al., Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res, 2007. 13(23): p. 7113-7118.
128. Einhorn, S. and D. Grander, Why do so many cancer patients fail to respond to interferon therapy? J Interferon Cytokine Res, 1996. 16(4): p. 275-281.
129. Harris, J.M. and R.B. Chess, Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov, 2003. 2(3): p. 214-221.
130. Vogel, C.L., et al., First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol, 2005. 23(6): p. 1178-1184.
131. Levy, Y., et al., Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. J Pediatr, 1988. 113(2): p. 312-317.
132. Satchi-Fainaro, R., R. Duncan, and C.M. Barnes, Polymer therapeutics for cancer: Current status and future challenges. Polym Ther II Polym Drugs Conjug Gene Deliv Syst, 2006. 193: p. 1-65.
133. Branco, M.C. and J.P. Schneider, Self-assembling materials for therapeutic delivery. Acta Biomater, 2009. 5(3): p. 817-831.
134. Soussan, E., et al., Drug delivery by soft matter: matrix and vesicular carriers. Angew Chem Int Ed, 2009. 48(2): p. 274-288.
135. Wu, X.L., et al., Tumor-targeting peptide conjugated pH-responsive micelles as a potential drug carrier for cancer therapy. Bioconjug Chem. 21(2): p. 208-213.
136. Kim, S., et al., Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction. Expert Opin Drug Deliv. 7(1): p. 49-62.
137. Lee, K.S., et al., Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat, 2008. 108(2): p. 241-250.
138. Saif, M.W., et al., Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. Cancer Invest. 28(2): p. 186-194.
139. Kim, D.W., et al., Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol, 2007. 18(12): p. 2009-2014.
140. Ahmed, F., et al., Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: pH-triggered release through copolymer degradation. Mol Pharm, 2006. 3(3): p. 340-350.
141. Haag, R. and F. Kratz, Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl, 2006. 45(8): p. 1198-1215.
142. Jain, K., et al., Dendrimer toxicity: Let's meet the challenge. Int J Pharm, 2010. 394(1-2): p. 122-142.
143. Qiu, L.Y. and Y.H. Bae, Polymer architecture and drug delivery. Pharm Res, 2006. 23(1): p. 1-30.
144. Namazi, H. and M. Adell, Dendrimers of citric acid and poly (ethylene glycol) as the new drug-delivery agents. Biomaterials, 2005. 26(10): p. 1175-1183.
145. Domanski, D.M., M. Bryszewska, and G. Salamonczyk, Preliminary evaluation of the behavior of fifth-generation thiophosphate dendrimer in biological systems. Biomacromolecules, 2004. 5(5): p. 2007-2012.
146. Agrawal, P., U. Gupta, and N.K. Jain, Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials, 2007. 28(22): p. 3349-3359.
147. Gillies, E.R., et al., Biological evaluation of polyester dendrimer: Poly(ethylene oxide) "Bow-Tie" hybrids with tunable molecular weight and architecture. Mo Pharm, 2005. 2(2): p. 129-138.
148. Malik, N., et al., Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of I-125-labelled polyamidoamine dendrimers in vivo. J Control Release, 2000. 65(1-2): p. 133-148.
149. Zhang, W., et al., Triazine dendrimers for drug delivery: Evaluation of solubilization properties, activity in cell culture, and in vivo toxicity of a candidate vehicle. Supramol Chem, 2003. 15(7-8): p. 607-617.
150. Singh, P., et al., Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug Chem, 2008. 19(11): p. 2239-2252.
151. Zhang, Y.Q., et al., Synthesis, biodistribution, and microsingle photon emission computed tomography (SPECT) imaging study of technetium-99m labeled PEGylated dendrimer poly(amidoamine) (PAMAM)-folic acid conjugates, 2010. J Med Chem, 53(8): p. 3262-3272.
152. Geng, Y., et al., Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol, 2007. 2(4): p. 249-255.
153. Saad, M., et al., Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging? J Control Release, 2008. 130(2): p. 107-114.
154. Gary, D.J., N. Puri, and Y.Y. Won, Polymer-based siRNA delivery: Perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release, 2007. 121(1-2): p. 64-73.
155. Sun, X.L. and N. Zhang, Cationic Polymer Optimization for Efficient Gene Delivery. Mini Rev Med Chem, 2010. 10(2): p. 108-125.
156. Akagi, D., et al., Biocompatible micellar nanovectors achieve efficient gene transfer to vascular lesions without cytotoxicity and thrombus formation. Gene Ther, 2007. 14(13): p. 1029-1038.
157. Ofek, P., et al., In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers. FASEB J. 24(9): p. 3122-3134.
158. Davis, M.E., et al., Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 464(7291): p. 1067-U140.
159. Greco, F. and M.J. Vicent, Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev, 2009. 61(13): p. 1203-1213.
160. Vicent, M.J., et al., Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew Chem Int Ed, 2005. 44(26): p. 4061-4066.
161. Santucci, L., et al., Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin. FASEB J., 2006: p. 05-4452fje.
162. Krakovicova, H., T. Etrych, and K. Ulbrich, HPMA-based polymer conjugates with drug combination. Eur J Pharm Sci, 2009. 37(3-4): p. 405-412.
163. Bae, Y., et al., Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. J Control Release, 2007. 122(3): p. 324- 330.
164. Wang, Y., et al., Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater, 2006. 5(10): p. 791-796.
165. Gaspar, R. and R. Duncan, Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv Drug Deliv Rev, 2009. 61(13): p. 1220-1231.
166. Maeda, H., Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem, 1992. 21(5): p. 797-802.